JAK/STAT pathway in pathology of rheumatoid arthritis (Review)

Rheumatoid arthritis (RA) is classified as an inflammatory, chronic autoimmune and disabling disease based on the intricate interplay between environmental and genetic factors. With a prevalence ranging from 0.3 to 1%, RA is the most prevalent inflammatory joint disease observed in adults. Disruptio...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2020-10, Vol.20 (4), p.3498-3503
Main Authors: Ciobanu, Dana Alexandra, Poenariu, Ioan Sabin, Crînguș, Laura-Ioana, Vreju, Florentin Ananu, Turcu-Stiolica, Adina, Tica, Andrei Adrian, Padureanu, Vlad, Dumitrascu, Roxana Mihaela, Banicioiu-Covei, Simona, Dinescu, Stefan Cristian, Boldeanu, Lidia, Siloși, Isabela, Ungureanu, Anca Marilena, Boldeanu, Mihail Virgil, Osiac, Eugen, Barbulescu, Andreea Lili
Format: Article
Language:English
Subjects:
Antigens
Arthritis
Autoimmune diseases
B cells
Cartilage
Cytokines
Disease
Fibroblasts
Growth factors
Immune system
Inflammation
Interleukins
Kinases
Ligands
Lymphocytes
Pathogenesis
Phosphorylation
Proteins
Review
Rheumatoid arthritis
Rheumatoid factor
Signal transduction
Tofacitinib
Tumor necrosis factor-TNF
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rheumatoid arthritis (RA) is classified as an inflammatory, chronic autoimmune and disabling disease based on the intricate interplay between environmental and genetic factors. With a prevalence ranging from 0.3 to 1%, RA is the most prevalent inflammatory joint disease observed in adults. Disruption of immune tolerance becomes evident when abnormal stimulation of the innate and adaptive immune system occurs. This cascade of events causes persistent joint inflammation, proliferative synovitis and, ultimately, damage of the underlying cartilage as well as the subchondral bone, leading to permanent joint destruction, deformity and subsequent loss of function. With cytokines being the key to a multitude of biological processes, including inflammation, hematopoiesis and overall immune response, one must inevitably look at the main pathways through which a significant number of those molecules exert their function. Janus kinase/signal transducers and activators of transcription (JAK/STATs) represent one such pathway and, recently, JAK inhibitors (JAKinibs) have shown promise in the treatment of several inflammatory diseases, including RA. This narrative review focuses on the intricate signaling pathways involved as well as on the clinical aspects and safety profiles of JAKinibs approved for the treatment of RA.
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2020.8982